Changes in US Clinician Waivers to Prescribe Buprenorphine Management for Opioid Use Disorder During the COVID-19 Pandemic and After Relaxation of Training Requirements

This case series examines numbers of US clinicians receiving waivers from the Drug Enforcement Administration allowing them to prescribe buprenorphine for opioid use disorder before and during the COVID-19 pandemic.

Detalles Bibliográficos
Autores principales: Spetz, Joanne, Hailer, Laurie, Gay, Caryl, Tierney, Matthew, Schmidt, Laura, Phoenix, Bethany, Chapman, Susan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2022
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9099425/
https://www.ncbi.nlm.nih.gov/pubmed/35552728
http://dx.doi.org/10.1001/jamanetworkopen.2022.5996

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9099425/
https://www.ncbi.nlm.nih.gov/pubmed/35552728
http://dx.doi.org/10.1001/jamanetworkopen.2022.5996

Ejemplares similares